Radezolid
CAS: 869884-78-6
Ref. 3D-FR103831
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued |
Product Information
- Acetamide, N-[[(5S)-3-[2-fluoro-4′-[[(1H-1,2,3-triazol-4-ylmethyl)amino]methyl][1,1′-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-
- Acetamide, N-[[(5S)-3-[2-fluoro-4′-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1′-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-
- N-[[(5S)-3-[2-Fluoro-4'-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide
Radezolid is a new chemical entity that belongs to the group of antibiotics. It has a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Radezolid inhibits bacterial growth by binding to the ATP-binding cassette transporter, preventing the uptake of fatty acids required for cell division. This drug also has bactericidal activity against Mycobacterium tuberculosis, Mycobacterium avium complex, and Enterococcus faecalis. Radezolid has been shown to have good pharmacokinetic properties in humans. In mice, it was rapidly absorbed from the gastrointestinal tract, with peak concentrations occurring at about 1 hour after oral administration. The elimination half-life was approximately 2 hours in humans and 4 hours in mice.
